The link between cervical cancer and Human Papillomavirus (HPV) has become clear over the past few decades—today we know that persistent infection with specific types of HPV account for nearly all cases of cervical cancer.
Cervical cancer rarely causes overt symptoms in its early stages—when treatment is most effective—so screening for the types of HPV infection at the greatest risk of progressing to cervical pre-cancer and cancer is imperative.
The cobas® HPV test is clinically validated to provide individual results for HPV 16 and HPV 18, along with a simultaneous, pooled result for other high-risk genotypes, all in one run, from one patient sample. By providing 3-in-1 results, clinicians are able to better risk stratify patients, and make patient management decisions with confidence.